{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T05:26:52Z","timestamp":1790573212261,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.annonc.2023.06.007","type":"journal-article","created":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T21:02:26Z","timestamp":1688504546000},"page":"796-805","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia"],"prefix":"10.1016","volume":"34","author":[{"given":"S.H.","family":"Cass","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.W.D.","family":"Tobin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.D.","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Gener-Ricos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.Z.","family":"Keung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.M.","family":"Burton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.L.","family":"McQuade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.J.","family":"Lazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Millward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Khoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Warburton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Guerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Haydon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Dearden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Menzies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.S.","family":"Carlino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.L.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Mollee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Burgess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Mapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Keane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Atkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.A.","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.N.","family":"Markovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.G.","family":"Call","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.J.","family":"Hampel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.V.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.","family":"Wargo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ferrajoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2023.06.007_bib1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Eichhorst","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2023.06.007_bib2","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/S0140-6736(18)30422-7","article-title":"Chronic lymphocytic leukaemia","volume":"391","author":"Hallek","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2023.06.007_bib3","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1200\/JCO.2012.43.4449","article-title":"Overall and cancer-specific survival of patients with breast, colon, kidney, and lung cancers with and without chronic lymphocytic leukemia: a SEER population-based study","volume":"31","author":"Solomon","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2023.06.007_bib4","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/CMR.0000000000000219","article-title":"Increased risk of melanoma in patients with chronic lymphocytic leukaemia: systematic review and meta-analysis of cohort studies","volume":"26","author":"Olsen","year":"2016","journal-title":"Melanoma Res"},{"key":"10.1016\/j.annonc.2023.06.007_bib5","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/j.1524-4725.2009.01447.x","article-title":"Effects of chronic lymphocytic leukemia on the development and progression of malignant melanoma","volume":"36","author":"Brewer","year":"2010","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.annonc.2023.06.007_bib6","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1200\/JCO.2011.34.9605","article-title":"Chronic lymphocytic leukemia is associated with decreased survival of patients with malignant melanoma and merkel cell carcinoma in a SEER population-based study","volume":"30","author":"Brewer","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2023.06.007_bib7","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/bjc.2011.313","article-title":"Second cancer incidence and cancer mortality among chronic lymphocytic leukaemia patients: a population-based study","volume":"105","author":"Royle","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.annonc.2023.06.007_bib8","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1182\/blood-2012-09-457531","article-title":"T\u00a0cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production","volume":"121","author":"Riches","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2023.06.007_bib9","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/sj.leu.2403907","article-title":"Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia","volume":"19","author":"Motta","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.annonc.2023.06.007_bib10","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2023.06.007_bib11","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V46.2.219.219","article-title":"Clinical staging of chronic lymphocytic leukemia","volume":"46","author":"Rai","year":"1975","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2023.06.007_bib12","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2023.06.007_bib13","first-page":"9","article-title":"Checkpoint blockade in melanoma patients with underlying chronic lymphocytic leukemia","volume":"44","author":"Smithy","year":"2021","journal-title":"J\u00a0Immunother"},{"key":"10.1016\/j.annonc.2023.06.007_bib14","doi-asserted-by":"crossref","first-page":"e21550","DOI":"10.1200\/JCO.2021.39.15_suppl.e21550","article-title":"Impact of immunotherapy on survival differences in patients with melanoma and chronic lymphocytic leukemia","volume":"39","author":"Tripathi","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2023.06.007_bib15","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2023.06.007_bib16","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2023.06.007_bib17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2023.06.007_bib18","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)","volume":"390","author":"Schachter","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2023.06.007_bib19","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2023.06.007_bib20","doi-asserted-by":"crossref","first-page":"9545","DOI":"10.1200\/JCO.2017.35.15_suppl.9545","article-title":"KEYNOTE-029: efficacy and safety of pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma","volume":"35","author":"Carlino","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2023.06.007_bib21","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1001\/jamadermatol.2013.6249","article-title":"Association of advanced leukemic stage and skin cancer tumor stage with poor skin cancer outcomes in patients with chronic lymphocytic leukemia","volume":"150","author":"Velez","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.annonc.2023.06.007_bib22","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ebiom.2018.05.019","article-title":"TP53 mutation as potential negative predictor for response of anti-CTLA-4 therapy in metastatic melanoma","volume":"32","author":"Xiao","year":"2018","journal-title":"EBioMedicine"},{"key":"10.1016\/j.annonc.2023.06.007_bib23","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/bjh.17337","article-title":"Risk of new malignancies among patients with CLL treated with chemotherapy: results of a Danish population-based study","volume":"193","author":"da Cunha-Bang","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.annonc.2023.06.007_bib24","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/bjh.18090","article-title":"Impact of chronic lymphocytic leukaemia on melanoma outcomes: a retrospective case-control study","volume":"197","author":"Jobson","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.annonc.2023.06.007_bib25","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1159\/000527631","article-title":"Resolution of melanoma to PD-1 blockade but simultaneous rapid progression of concomitant chronic lymphocytic leukemia","volume":"146","author":"Burgess","year":"2023","journal-title":"Acta Haematol"},{"key":"10.1016\/j.annonc.2023.06.007_bib26","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2023.06.007_bib27","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2023.06.007_bib28","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1182\/blood-2015-01-622936","article-title":"PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia","volume":"126","author":"McClanahan","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2023.06.007_bib29","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1182\/blood-2017-02-765685","article-title":"Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL","volume":"129","author":"Ding","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2023.06.007_bib30","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1182\/blood.V128.22.59.59","article-title":"Nivolumab combined with ibrutinib for CLL and Richter transformation: a phase II trial","volume":"128","author":"Jain","year":"2016","journal-title":"Blood"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753423007354?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753423007354?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T06:16:21Z","timestamp":1760336181000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753423007354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S0923753423007354"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2023.06.007","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2023.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Society for Medical Oncology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}